NCT02422641: Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

NCT02422641
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Leptomeningeal Disease
Additional Notes: Patients must have evidence of leptomeningeal disease (LMD) with or without brain metastases
Exclusions: 
https://ClinicalTrials.gov/show/NCT02422641

Comments are closed.

Up ↑